You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Comparison of FDG PET/CT and Gadolinium-Enhanced MRI for the Detection of Bone Metastases in Patients With Cancer: A Meta-analysis

Duo, Jian MD, PhD*; Han, Xiuxin MD, PhD*; Zhang, Li MD; Wang, Guowen MD*; Ma, Yulin MD*; Yang, Yun MD*

Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182817af3
Original Articles
Abstract

Objective: At present, the differences in the efficacy between PET/CT and MRI for the detection of bone metastases in patients with cancer have not been clearly delineated. We performed a meta-analysis to compare the performance of FDG PET/CT with that of gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer.

Methods: Studies about PET/CT and MRI for the detection of bone metastases were systematically searched in the MEDLINE, EMBASE, and EBM Review databases. We calculated sensitivities, specificities, diagnostic odds ratios, positive likelihood ratios, negative likelihood ratios (NLR), and constructed summary receiver operating characteristic curves using bivariate regression models for PET/CT and MRI, respectively.

Results: Across 9 studies (1116 patients), FDG PET/CT has similar patient-based sensitivity (0.803 vs 0.837), specificity (0.989 vs 0.977), diagnostic odds ratio (309.0 vs 221.9), positive likelihood ratio (61.7 vs 37.0), and negative likelihood ratio (0.200 vs 0.167) with gadolinium-enhanced MRI. Areas under the curve with 95% confidence interval for FDG PET/CT and gadolinium-enhanced MRI were 0.99 (0.98–0.99) and 0.98 (0.97–0.99), respectively.

Conclusions: FDG PET/CT and gadolinium-enhanced MRI have excellent diagnostic performance for the detection of bone metastases in patients with cancer.

Author Information

From the Departments of *Bone and Soft Tissue Tumors and †Gynecology Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China.

Received for publication September 2, 2012; revision accepted November 30, 2012.

Drs Duo and Han contributed equally to this work as first author.

Conflicts of interest and sources of funding: none declared.

Reprints: Jian Duo, MD, PhD, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, He Xi District, Tianjin 300060, People’s Republic of China. E-mail: duojian101@sohu.com.

© 2013 by Lippincott Williams & Wilkins